Can thiệp Động mạch vành qua da: Bóng, Stent và các loại giá đỡ
Tóm tắt
Trong bài bình luận này, các thành tựu trong lĩnh vực can thiệp động mạch vành qua da được phác họa trong suốt quá trình phát triển 40 năm qua. Bài viết này đề cập đến những bước phát triển quan trọng, bao gồm những ca thông tim, chụp động mạch vành, nong động mạch vành bằng bóng đầu tiên cho đến các kỹ thuật ngày càng được tiêu chuẩn hóa, đặt stent động mạch vành và tối ưu hóa điều trị các thuốc chống đông máu đi kèm, stent phủ thuốc và bóng phủ thuốc cho đến các loại stent phủ thuốc kim loại hay làm bằng polyme tự tiêu sinh học
Tài liệu tham khảo
1. King SB 3rd (1998) The development of interventional cardiology. J Am Coll Cardiol 31:64b–88b.
2. Wierny L, Plass R, Porstmann W (1974) Long-term results in 100 consecutive patients treated by transluminal angioplasty. Radiol- ogy 112:543–548.
3. Kaltenbach M (2002) Evolution of interventional cardiology in Germany. J Interv Cardiol 15:33–39.
4. Simpson JB, Baim DS, Robert EW, Harrison DC (1982) A new catheter system for coronary angioplasty. Am J Cardiol 49:1216–1222
5. Kaltenbach M (1984) The long wire technique - a new tech- nique for steerable balloon catheter dilatation of coronary artery stenoses. Eur Heart J 5:1004–1009.
6. Bonzel T, Wollschläger H, Just H (1986) A new catheter system for the mechanical dilatation of coronary stenoses with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. Biomed Tech 31:195–200.
7. Byrne RA, Stone GW, Ormiston J, Kastrati A (2017) Coronary balloon angioplasty, stents, and scaffolds. Lancet 390:781–792.
8. Byrne RA, Joner M, Kastrati A (2015) Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 36:3320–3331
9. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after trans- luminal angioplasty. N Engl J Med 316:701–706
10. Sigwart U (1995) Non-surgical myocardial reduction for hyper- trophic obstructive cardiomyopathy. Lancet 346:211–214.
11. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al (1994) A comparison of balloon-expanda- ble-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495.
12. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496–501.
13. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Had- amitzky M et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089.
14. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J et al (2000) Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 50:290–297.
15. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL et al (2011) Stent thrombo- genicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123:1400–1409.
16. Simon C, Palmaz JC, Sprague EA (2000) Influence of topography on endothelialization of stents: clues for new designs. J Long Term Effects Med Implants 10:143–151.
17. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neu- mann FJ et al (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STE- REO) trial. Circulation 103:2816–2821.
18. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al (2003) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283–1288.
19. Schulz S, Mehilli J, Schomig A, Kastrati A (2010) ISAR-a story of trials with impact on practice. Circ J 74:1771–1778.
20. Palmaz JC, Benson A, Sprague EA (1999) Influence of surface topography on endothelialization of intravascular metallic mate- rial. J Vasc Interv Radiol 10:439–444.
21. Nakayama Y, Nishi S, Ishibashi-Ueda H, Matsuda T (2000) Surface microarchitectural design in biomedical applications: in vivo analysis of tissue ingrowth in excimer laser-directed micropored scaffold for cardiovascular tissue engineering. J Biomed Mater Res 51:520–528.
22. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirsch- inger J et al (2005) Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a rand- omized double-blind controlled trial. Catheter Cardiovasc Interv 65:374–380.
23. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al (2002) A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780.
24. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) One-year
clinical results with the slow- release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947.
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202
26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948
27. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al (2005) Inhibition of neointima formation by a novel drug- eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25:748–753
28. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzen- staller T et al (2005) Prevention of restenosis by a novel drug- eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26:1475–1481
29. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al (2008) Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29:1975–1982
30. Desch S, Schloma D, Mobius-Winkler S, Erbs S, Gielen S, Linke A et al (2011) Randomized comparison of a polymer-free siroli- mus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. JACC Cardiovasc Interv 4:452–459
31. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R et al (2009) The pre-clinical assessment of rapamy- cin-eluting, durable polymer-free stent coating concepts. Bioma- terials 30:632–637
32. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL et al (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Effi- cacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 30:2441–2449
33. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hopp- mann P et al (2016) Five-year outcomes from a trial of three
